Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma

Alan Katz

Status: Completed

Conditions: Liver Neoplasms

Study type: Observational

Funder types: Other

Identifiers

NCT02489838

ULAB11069

Details and patient eligibility

About

To Calculate the amount radiation the lung receives in patients receiving Yttrium-90 for Liver Cancer.

Full description

To calculate the delivered lung dose using quantitative volumetric analysis in a cohort of patients with unresectable hepatocellular carcinoma who undergo selective internal radiation therapy (SIRT) with Yttrium-90 glass microspheres (TheraSphere®)-and compare this analysis to the lung dose estimated by established criteria. In addition, this study, will summarize the pre and post-treatment clinical data to describe the URMC Y-90 experience.

Enrollment: 56 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults ≥ 18 years with no upper limit.-Receiving Y-90 Therasphere liver directed therapy

• Pathology proven diagnosis of hepatocellular carcinoma, metastatic colon cancer or other metastatic diseases to be treated with SIRT (Y-90)

• surgical resection not feasible at time of initiation of pre-treatment workup

  -> 6 months projected life span

• ECOG 0-2

Exclusion criteria

• previous radioembolization of one or more liver lobes or segments without available treatment planning and procedural documentation ie. at another facility prior to URMC Y-90 radioembolization.